弱碱性药物与酸性共形成物的共晶体如何调节溶解度和稳定性。
How cocrystals of weakly basic drugs and acidic coformers might modulate solubility and stability.
作者信息
Kuminek G, Rodríguez-Hornedo N, Siedler S, Rocha H V A, Cuffini S L, Cardoso S G
机构信息
Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
出版信息
Chem Commun (Camb). 2016 Apr 30;52(34):5832-5. doi: 10.1039/c6cc00898d. Epub 2016 Apr 4.
Abstract
Cocrystals of a weakly basic drug (nevirapine) with acidic coformers are shown to alter the solubility dependence on pH, and to exhibit a pHmax above which a less soluble cocrystal becomes more soluble than the drug. The cocrystal solubility advantage can be dialed up or down by solution pH.
摘要
一种弱碱性药物（奈韦拉平）与酸性共形成物的共晶体被证明会改变溶解度对pH值的依赖性，并表现出一个pH最大值，高于该值时，溶解度较低的共晶体比药物更易溶解。共晶体的溶解度优势可通过溶液pH值进行调节。
相似文献
1
How cocrystals of weakly basic drugs and acidic coformers might modulate solubility and stability.弱碱性药物与酸性共形成物的共晶体如何调节溶解度和稳定性。
Chem Commun (Camb). 2016 Apr 30;52(34):5832-5. doi: 10.1039/c6cc00898d. Epub 2016 Apr 4.
2
Mechanistic Basis of Cocrystal Dissolution Advantage.共晶溶解优势的机制基础。
J Pharm Sci. 2018 Jan;107(1):380-389. doi: 10.1016/j.xphs.2017.09.014. Epub 2017 Oct 6.
3
Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization.共晶溶解作为pH值和胶束增溶作用的函数的机理分析
Mol Pharm. 2016 Mar 7;13(3):1030-46. doi: 10.1021/acs.molpharmaceut.5b00862. Epub 2016 Feb 15.
4
pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media.在水介质中，依托 pH 值的变化，吲哚美辛-糖精和卡马西平-糖精共晶的溶解度。
Mol Pharm. 2012 Sep 4;9(9):2605-12. doi: 10.1021/mp300189b. Epub 2012 Aug 23.
5
Cocrystal solubility product analysis - Dual concentration-pH mass action model not dependent on explicit solubility equations.共晶溶解度乘积分析 - 双浓度-pH 质量作用模型不依赖于显式溶解度方程。
Eur J Pharm Sci. 2017 Dec 15;110:2-18. doi: 10.1016/j.ejps.2017.03.049. Epub 2017 Apr 6.
6
Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.理解共晶和盐在水溶液中溶解度的差异。
J Pharm Sci. 2018 Jan;107(1):113-120. doi: 10.1016/j.xphs.2017.10.033. Epub 2017 Oct 31.
7
Cocrystals Mitigate Negative Effects of High pH on Solubility and Dissolution of a Basic Drug.共晶减轻高pH值对碱性药物溶解度和溶出度的负面影响。
Cryst Growth Des. 2018 Mar 7;18(3):1358-1366. doi: 10.1021/acs.cgd.7b01206. Epub 2018 Feb 14.
8
Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals.基于药物降解途径的共晶形成剂选择：阿德福韦酯-糖精和阿德福韦酯-烟酰胺共晶的案例研究。
Int J Pharm. 2012 Nov 15;438(1-2):327-35. doi: 10.1016/j.ijpharm.2012.09.027. Epub 2012 Sep 16.
9
Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutants.对K103N和Y181C HIV-1逆转录酶突变体不敏感的奈韦拉平衍生物的设计
SAR QSAR Environ Res. 2006 Apr;17(2):183-94. doi: 10.1080/10659360600636147.
10
Crystal engineering of stable temozolomide cocrystals.稳定替莫唑胺共晶的晶体工程。
Chem Asian J. 2012 Oct;7(10):2274-85. doi: 10.1002/asia.201200205. Epub 2012 May 21.
引用本文的文献
1
Discovery of Cilnidipine Cocrystals with Enhanced Dissolution by the Use of Computational Tools and Semiautomatic High-Throughput Screening.利用计算工具和半自动高通量筛选发现具有增强溶出度的西尼地平共晶体
Cryst Growth Des. 2025 Apr 29;25(10):3374-3385. doi: 10.1021/acs.cgd.5c00184. eCollection 2025 May 21.
2
Virtual Screening, Structural Analysis, and Formation Thermodynamics of Carbamazepine Cocrystals.卡马西平共晶体的虚拟筛选、结构分析及形成热力学
Pharmaceutics. 2023 Mar 3;15(3):836. doi: 10.3390/pharmaceutics15030836.
3
Tailoring Chlorthalidone Aqueous Solubility by Cocrystallization: Stability and Dissolution Behavior of a Novel Chlorthalidone-Caffeine Cocrystal.通过共结晶调整氯噻酮的水溶性：新型氯噻酮-咖啡因共晶体的稳定性和溶解行为
Pharmaceutics. 2022 Jan 30;14(2):334. doi: 10.3390/pharmaceutics14020334.
4
Continuous Manufacture and Scale-Up of Theophylline-Nicotinamide Cocrystals.茶碱-烟酰胺共晶体的连续制造与放大生产
Pharmaceutics. 2021 Mar 20;13(3):419. doi: 10.3390/pharmaceutics13030419.
5
Potential Anti-Tumor Drug: Co-Crystal 5-Fluorouracil-nicotinamide.潜在的抗肿瘤药物：5-氟尿嘧啶-烟酰胺共晶体。
ACS Omega. 2020 Jun 24;5(26):15777-15782. doi: 10.1021/acsomega.9b03574. eCollection 2020 Jul 7.
6
Multidrug Cocrystal of Anticonvulsants: Influence of Strong Intermolecular Interactions on Physiochemical Properties.抗惊厥药的多药共晶：强分子间相互作用对物理化学性质的影响。
Cryst Growth Des. 2017 Oct 4;17(10):5012-5016. doi: 10.1021/acs.cgd.7b00741. Epub 2017 Sep 8.
7
Cocrystals Mitigate Negative Effects of High pH on Solubility and Dissolution of a Basic Drug.共晶减轻高pH值对碱性药物溶解度和溶出度的负面影响。
Cryst Growth Des. 2018 Mar 7;18(3):1358-1366. doi: 10.1021/acs.cgd.7b01206. Epub 2018 Feb 14.
8
Cocrystal Solubility Product Prediction Using an in combo Model and Simulations to Improve Design of Experiments.使用组合模型和模拟进行共晶溶解度乘积预测，以改进实验设计。
Pharm Res. 2018 Feb 2;35(2):40. doi: 10.1007/s11095-018-2343-3.
9
Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.理解共晶和盐在水溶液中溶解度的差异。
J Pharm Sci. 2018 Jan;107(1):113-120. doi: 10.1016/j.xphs.2017.10.033. Epub 2017 Oct 31.
10
Mechanistic Basis of Cocrystal Dissolution Advantage.共晶溶解优势的机制基础。
J Pharm Sci. 2018 Jan;107(1):380-389. doi: 10.1016/j.xphs.2017.09.014. Epub 2017 Oct 6.
本文引用的文献
1
Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization.共晶在生物相关介质中的溶解及其从药物溶解情况的预测
J Pharm Sci. 2015 Dec;104(12):4153-4163. doi: 10.1002/jps.24640. Epub 2015 Sep 21.
2
Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents.共晶转变点：共晶溶解度、药物溶解度及增溶剂的作用
Mol Pharm. 2015 Oct 5;12(10):3535-46. doi: 10.1021/acs.molpharmaceut.5b00111. Epub 2015 Aug 28.
3
Thermodynamic Solubility Profile of Carbamazepine-Cinnamic Acid Cocrystal at Different pH.卡马西平-肉桂酸共晶体在不同pH值下的热力学溶解度曲线
J Pharm Sci. 2015 Aug;104(8):2559-65. doi: 10.1002/jps.24525. Epub 2015 Jun 10.
4
pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media.在水介质中，依托 pH 值的变化，吲哚美辛-糖精和卡马西平-糖精共晶的溶解度。
Mol Pharm. 2012 Sep 4;9(9):2605-12. doi: 10.1021/mp300189b. Epub 2012 Aug 23.
5
Engineering cocrystal solubility, stability, and pH(max) by micellar solubilization.通过胶束增溶作用工程共晶溶解度、稳定性和 pH(max)。
J Pharm Sci. 2011 Dec;100(12):5219-34. doi: 10.1002/jps.22725. Epub 2011 Sep 9.
6
Solid-state characterization of nevirapine.奈韦拉平的固态表征
Indian J Pharm Sci. 2008 Sep;70(5):619-30. doi: 10.4103/0250-474X.45401.
7
Solubility of sparingly-soluble ionizable drugs.微溶性可电离药物的溶解度
Adv Drug Deliv Rev. 2007 Jul 30;59(7):568-90. doi: 10.1016/j.addr.2007.05.008. Epub 2007 May 29.
8
Salt formation to improve drug solubility.通过盐形成来提高药物溶解度。
Adv Drug Deliv Rev. 2007 Jul 30;59(7):603-16. doi: 10.1016/j.addr.2007.05.010. Epub 2007 May 29.
9
Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug.
AIDS Res Hum Retroviruses. 1992 Feb;8(2):145-52. doi: 10.1089/aid.1992.8.145.
Zotero 插件